Johnson & Johnson's research and development, manufacturing, and sale of healthcare products include pharmaceuticals, medical devices, and diagnostics. The company aims to improve access and create healthier communities.

Johnson & Johnson

Seventure Partners is a French venture capital firm targeting in Tech/Digital and Life Sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion. Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with € 1 billion under management as of December 31, 2023. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations. Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors. The different funds/verticals on which Seventure Partners are focusing on today: - Life Sciences : Biotech, Healthcare, Nutrition - Tech/Digital : B2B SaaS, Fintech, Retailtech, Cybersecurity - Sports & Wellbeing - Blue Economy

Seventure Partners

Mayo Clinic, a not-for-profit medical group practice, provides medical care, research, and education services. It offers medical care services in various specialties, including diabetes and endocrinology, gastroenterology, gynecology, cancer, neurology and neurosurgery, orthopedics, pulmonology, rheumatology, nephrology, urology, and cardiology and heart surgery.

Mayo Clinic

French Investment Fund was added in 2013.

French Investment Fund

Century Partner mission is to facilitate holistic revitalization through sustainable residential housing development that embraces grass roots community outreach and the power of creative place-making.

CenturyPartners

aMoon is a leading healthtech & life sciences venture fund founded by Marius Nacht and Dr. Yair Schindel. Their team is passionate about building successful businesses and helping biopharma, digital health and medical technology companies realize their potential. They partner with management teams who use technology and cutting-edge science to accelerate cures for the world’s most life-threatening conditions and those providing solutions for global healthcare’s biggest cost drivers.

aMoon Fund

10D is a venture capital firm that seeks to invest in early-stage Seed and Series A rounds in digital health, fintech, insurance, computer vision, and artificial intelligence startups. The firm previously operated under the temporary name, Ofek Ventures. It pursues startups that disrupt markets by using deep technology, creating new business models, and featuring entrepreneurial teams. 10D makes $1 million to $5 million in initial investments and follow-on investments of up to $10 million. Its portfolio companies include Seebo, the developer of artificial intelligence technologies for industrial plants; StuffThatWorks, a creator of a new healthcare database based on crowdsourcing; DayTwo, a provider of customized nutritional guidelines based on the gut microbiome for the purpose of lowering blood sugar levels; and additional investments. It was led by Yahal Zilka, Rotem Eldar, and Itay Rand in Tel Aviv, Israel.

Cathay Innovation is a global venture capital firm, created in affiliation with Cathay Capital, investing in startups at the center of digital revolution across North America, Latin America, Europe, Asia and Africa. Its global platform unifies technology investment across continents, investors, entrepreneurs and leading corporations to accelerate startup growth with access to new markets, invaluable industry knowledge and introductions to potential partners from the start. As a multistage fund with over $1.5 billion assets under management and offices across San Francisco, New York, Paris, Shanghai, Beijing and Singapore, Cathay Innovation partners with visionary entrepreneurs and startups positively impacting the world through technology.  To learn more, please visit www.cathayinnovation.com or follow us on Twitter @Cathayinnov.

Cathay Innovation

Samsung NEXT Ventures is an investment arm of Samsung NEXT, a multifaceted innovation group within Samsung Electronics dedicated to identifying new growth opportunities that will define the next decade. The firm prefers to invest in artificial intelligence, fintech, blockchain, health technology, infrastructure, and media technology sectors.

Samsung NEXT

Targeting early stage companies with the intent uncover and nourish Consumer Digital Health solutions that will augment and eventually revolutionize the way people manage their health and wellness. Such solutions – that converge healthcare with the world of retail - could benefit from the Group’s global footprint, e.g. 14,500 retail stores in 24 markets

Longliv Ventures

Micron Ventures offers investment solutions to early-stage companies in the technology sector.

Micron Ventures

Poalim Capital Markets is a boutique investment banking firm that offers financial advisory services. The firm provides mergers and acquisitions, corporate divestiture, corporate recapitalizations and restructurings, leveraged buyouts, valuations and fairness opinions, private placements, and initial public offerings advisory services. Additionally, it offers feasibility study, private placement memorandum and investor presentation preparation, client road-show organization, and term sheet negotiation and closing services. The firm caters to corporations, institutional investors, and high net-worth individuals. It has strategic alliances with William Blair & Company, YES BANK, and Poalim Asia Direct. The firm was founded in 1990 and is based in Tel Aviv, Israel. Poalim Capital Markets Ltd. operates as a subsidiary of Bank Hapoalim B.M.

Poalim Equity

Founded in 2019, Volta Circle is an early-stage evergreen VC investor, based in London and backed by a single LP. The firm invests in technology-driven startups across three core verticals covering food systems, circularity and climate, with a mission to enable founders to create maximum value, scale, and impact. The team is based between Geneva, Milan, London and Bangkok.

Volta Circle

La Maison Partners is a venture capital fund that invests in industry, technology, and finance. The fund supports its portfolio companies with its strong relationship network and by leveraging synergies with its shareholders, which enables collaboration with European industries.  La Maison Partners was founded in 2014 and is headquartered in Paris, France.

La Maison Partners

DayTwo

DayTwo is a precision nutrition company that uses food as medicine to enable a path to remission for metabolic diseases including diabetes, prediabetes, clinical obesity, and NAFLD.  DayTwo's groundbreaking scientific discovery, published in CELL (2015) and JAMA (2019) determined that people respond differently to the same food, thus knowing what food “works” for each person is crucial to an effective care plan.  DayTwo uses gut microbiome sequencing (stool sample, akin to Cologuard) to create Food Prescriptions™ for each patient which balance blood sugar levels, improve energy, manage hunger, and help members lose weight.  DayTwo virtual care solution is delivered through Certified Diabetes Care and Education Specialists and Registered Dietitians using a digital app to track progress and communicate with members.

<div>DayTwo is a health technology company specializing in personalized nutrition and wellness solutions based on gut microbiome analysis. The company integrates gut microbiome sequencing, AI, and virtual care to provide a sustainable path to remission for metabolic diseases (i.e., diabetes, prediabetes, clinical obesity, and non-alcoholic fatty liver disease).&nbsp;</div>

Longevity Tech

DayTwo is a personalized nutrition company that uses an individual's gut microbiome data to provide customized dietary recommendations aimed at improving metabolic health conditions such as type two diabetes and obesity. The company's science is based on groundbreaking research conducted at the <a href="https://www.daytwo.com/blog/introduction-to-daytwo-and-our-science/">Weizmann Institute of Science</a> in Israel, which demonstrated that people's blood sugar responses to the same foods can vary significantly due to differences in their gut microbiome composition.

Functional Nutrition

Healthtech startup DayTwo shuts down

<div>
 
 DayTwo is a health technology company specializing in personalized nutrition and wellness solutions based on gut microbiome analysis. The company integrates gut microbiome sequencing, AI, and virtual care to provide a sustainable path to remission for metabolic diseases (i.e., diabetes, prediabetes, clinical obesity, and non-alcoholic fatty liver disease).&nbsp;
 
 
 The company offers gut microbiome profiling to predict blood sugar response to foods and dedicated virtual care. The main product of DayTwo is a glycemic-control solution, which is intended for persons with Type 2 diabetes. It is said to assist in balancing blood sugar levels, lowering HbA1C, and losing weight.&nbsp;
 
 
 Key customers and partnerships
 
 
 In January 2024, the company partnered with Pragma Bio, a technology-driven drug discovery firm, to gain a thorough understanding of the connections between the human gut and Inflammatory Bowel Disease (IBD). This partnership prioritized using advanced technology and comprehensive patient data, including metagenomic data, to address unmet needs in the IBD field. The primary goal was to uncover biomarkers and develop therapeutics through foundational discoveries.
 
 
 In November 2020, the company partnered with Florida Health Alliance to develop precision nutrition targeting metabolic disease.
 
 
 Funding and Financials
 
 
 In August 2021, DayTwo raised USD 37 million in funding to support the expansion of chronic disease solutions for employers, health plans, and health systems and to address the growing demand for its virtual care solution for metabolic diseases, including diabetes, prediabetes, and obesity.
 
</div>

Mitrix Bio addresses mitochondrial dysfunction by developing bioreactor-grown mitochondria to be transplanted into the human body to regenerate organs, reverse age-related disease, and support other longevity therapies. Large-scale mitochondrial transfusion could potentially treat Alzheimer's, Parkinson's, AMD, glaucoma, infectious disease, and other age-related diseases, along with children's mitochondrial mutation diseases. The company believes that the same technique can be used in healing and reducing frailty for the aged, speeding healing of wounded soldiers, or combating aging itself. The company is developing technologies and infrastructure targeting to reverse mitochondrial mtDNA degeneration targeting parts of the body that most commonly experience mitochondrial dysfunction. The company has six programs at preclinical stages in its pipeline (as of October 2023). These programs are focused on immunology (infectious diseases), neurology (Alzheimer's/Parkinson’s), ophthalmology (AMD/glaucoma), dermatology (aking aging/wound healing), musculo-skeletal (sarcopenia, frailty), and organs (liver/kidney).

Mitrix Bio

Sierra Sciences engages in research to develop therapeutics targeting aging based on telomeres. These get shorter as people age and lead to various diseases. The company aims to extend the human lifespan and healthspan based on addressing telomere shortening as a solution to address effects of human aging. The company receives royalties from the sale of Product B, a nutraceutical supplement developed in a partnership and distributed through Isagenix. The company develops therapeutics focused on pharmaceuticals to slow and reverse the aging process, nutraceuticals to slow and reverse aging, telomere protection, telomere length measurement, cancer diagnostics, cancer treatments, telomerase gene therapy, immortal pet cloning, and human growth hormones.

Sierra Sciences

Turn.bio is a biotech company developing therapies based on epigenetic reprogramming and reverse cellular aging. The company develops mRNA medicines that induce the body to heal itself by instructing specific cells to fight disease or repair damaged tissue. This is focused on reprogramming the epigenome to restore capabilities that are often lost with age. Its proprietary ERA Platform can reportedly be used to revitalize different cells throughout the body. The company is exploring its applicability across multiple therapeutic areas, including dermatologic conditions, immunology, osteoarthritis, and ophthalmology. The platform is claimed to enable control of the time, duration, and dosage of transcription factors to optimize the mRNA cocktail for each indication. This reportedly allows control of reprogramming, moving the epigenome to a more youthful state step-by-step by carefully pulsing the cell with the transcription factors. The company claims to have discovered that the use of quiescent stem cells can significantly help to repair or replace specific types of damaged tissue. In these cases, the company reportedly deploys its Artificial Niche (AN) technology to protect the stem cells. AN technology combines stem-cell biology with biomolecular materials engineering and micro-fabrication technologies to generate novel cell-culture platforms that mimic crucial biochemical or structural aspects of the niche. turn.bio’s novel eTurna Platform can reportedly deliver a variety of cargoes requiring different routes of administration and be fine-tuned and targeted to specific tissue and cells. Funding and financials In July 2022, biotech company VitaDAO made a USD 1,000,000 investment into turn.bio. The investment was intended to fund turn.bio’s preclinical efficacy testing phase for mRNA therapeutics for dermatological and ophthalmological longevity research.

Turn.bio

<div>
 
 AgeX Therapeutics is a biotech company engaged in the development and commercialization of novel therapeutics focused on aging.&nbsp;
 
 
 
 
 The company is building upon the foundation of its proprietary technologies, such as PureStem and induced Tissue Regeneration, to develop medicines targeting aging and related diseases. Through PureStem, the company claims to have the ability to generate pluripotent stem cell-derived young cells of any type for potential application in a range of degenerative diseases of aging. iTM is claimed to be the company's longevity platform intending to unlock cellular immortality and regenerative capacity to reverse age-related changes in the body.
 
 
 
 
 Its product pipeline includes two cell-based and two iTR-based product candidates in development: AGEX-BAT1 and AGEX-VASC1.
 
 
 AGEX-BAT1 is a cell therapy product candidate in the discovery stage of development utilizing PSC-derived brown adipocytes for the treatment of certain age-related metabolic disorders, such as type 2 (adult-onset) diabetes and obesity. AGEX-VASC1 is a cell-based therapy in the discovery stage of development, composed of young regenerative vascular-forming cells.&nbsp;
 
 
 
 
 The company was founded by leading gerontologist, bioentrepreneur, and Ph.D. holder Dr. Michael D. West,&nbsp; a highly-regarded pioneer in cellular aging, stem cell research, telomerase, and cloning.
 
 
 
 
 In August 2023, the company entered a merger agreement with Serina Therapeutics, a privately held, clinical-stage biotech company developing a pipeline of therapies for the treatment of Parkinson&rsquo;s disease and other neurological diseases. Under this, Serina merged with a wholly-owned subsidiary of AgeX therapeutics in an all-stock transaction. The combined company continues under the &ldquo;Serina Therapeutics&rdquo; name and focuses on advancing Serina&rsquo;s pipeline of small-molecule drug candidates targeting central nervous systems indications.
 
 
 
 
 Funding and financials
 
 
 
 
 The company recorded total revenue of USD 34 million in 2022, compared to USD 144 million in 2021 (77% decrease). This is due to absence of grant revenues in 2022, as opposed to 2021, where grant revenue was USD 104 million. Net loss reported for 2022 was USD 10.5 million, compared to the loss of USD 8.7 million recorded in the preceding year.
 
 
 
 
 
</div>

AgeX Therapeutics

<div>
 
 UNITY Biotechnology develops therapeutics targeting age-related diseases, particularly focusing on therapy in ophthalmologic diseases, including diabetic macular edema and age-related neurologic conditions.
 
 
 
 
 Its therapeutics are intended to selectively eliminate or modulate senescent cells to slow down, stop, or even reverse age-related disease and restore aging or damaged tissue to a more functionally healthy state. The approach is expected to remedy diseases of aging, such as retinopathies, neurodegenerative disorders, fibrosis, and cancer.&nbsp;
 
 
 
 
 The company&rsquo;s lead drug candidate, UBX1325, is evaluated for the treatment of age-related diseases of the eye, including diabetic macular edema. The small molecule targets Bcl-xL, a protein that senescent cells rely on for survival. It is claimed that UBX1325 demonstrated a statistically significant and clinically meaningful improvement in mean best corrected visual acuity (BCVA) across 48 weeks compared to sham treatment in the Phase II BEHOLD study in patients with DME. A Phase IIb study (ASPIRE) was enrolling patients with DME to evaluate UBX1325 head-to-head against aflibercept.
 
 
 
 
 UNITY Biotechnology was also developing programs targeting the Tie2 signaling pathway for therapeutic benefit. Tie2 pathway activity declines with age and causes the loss of vascular barrier integrity and diseased blood vessel formation in the eye. The Tie2/VEGF bispecific molecule targets two pathways believed to be core to disease progression in DME and AMD. Another program directed at Tie2 activation is in preclinical studies for multiple indications.
 
 
 
 
 The company's neurology programs intend to explore new mechanisms for cognitive benefit, and the company licensed its &alpha;-Klotho program, UBX2089, to Jocasta Neuroscience for development and commercialization in cognitive dysfunction associated with neurological and psychiatric conditions.
 
 
 
 
 
</div>

UNITY Biotechnology

Companies conducting R&D on cell and gene therapies that aim to repair or replace dysfunctional cells to address the root cause of age-related diseases

Companies involved in the development of novel small molecules or chemical drugs that target specific proteins or pathways in the body to treat age-related diseases as well as the identification of existing drugs that can be repurposed for the treatment of such diseases

Platforms and tools that collect and analyze patient data to detect, prevent, and monitor age-related damage

Dietary supplements and wellness products that are developed through scientific approaches to slow down age-related damage

Companies developing therapies for age-related sensory deficiencies such as vision and hearing loss

Companies in the neurotechnology sector that develop tools such as neuroimaging and neurostimulation devices; pharmaceutical drugs and therapies aimed at treating age-related neurological conditions

Diagnostic tests and services focused on assessing the health of an individual's gut microbiome and their metabolic processes to identify internal age-related issues

Platforms and tools that provide personalized remedies for general well-being and to mitigate the risk of age-related diseases

Genomics is used for diagnostics and to offer tailored treatment for age-related diseases

Offers digital platforms and devices that allow individuals to measure, track, and potentially modify the physiological changes associated with aging

AL/ML is used in drug discovery and development as well as diagnostic tools to support longevity-related treatments

DayTwo is a personalized nutrition company that uses an individual's gut microbiome data to provide customized dietary recommendations aimed at improving metabolic health conditions such as type two diabetes and obesity. The company's science is based on groundbreaking research conducted at the <a href="https://www.daytwo.com/blog/introduction-to-daytwo-and-our-science/">Weizmann Institute of Science</a> in Israel, which demonstrated that people's blood sugar responses to the same foods can vary significantly due to differences in their gut microbiome composition.DayTwo analyzes a customer's gut microbiome through DNA sequencing of a stool sample, along with other health markers like blood sugar levels. Using this data, along with AI and machine learning algorithms, the company generates personalized meal plans and food scores that predict how an individual's blood sugar levels will respond to specific foods and meals. This approach moves beyond traditional one-size-fits-all dietary recommendations and allows users to make informed choices about which foods to consume or avoid based on their unique biology.Key customers and partnershipsIn <a href="https://www.businesswire.com/news/home/20240117177436/en/Pragma-Bio-and-DayTwo-Join-Forces-to-Illuminate-the-Path-to-IBD-Disease-Management">January 2024</a>, the company partnered with Pragma Bio, a tech-enabled drug discovery company, to collaborate on understanding the link between the human gut and Inflammatory Bowel Disease (IBD). Through the partnership, the companies planned to collaborate to develop biomarkers and therapeutics.

Youniq Health is a US-based company that has developed an AI-powered app to provide personalized nutrition plans tailored to individual users' health goals, dietary preferences, and biological data. The app utilizes an algorithm that processes various data points, such as blood samples, microbiome tests, genomic information, biometrics, and food preferences, to generate customized recipes and meal plans. These recipes are designed to align with the user's specific objectives, whether it's improving sleep, managing diabetes, managing chronic conditions, or boosting the immune system.A key feature is its ability to create new recipes in real time, complete with accompanying images. The app's AI technology generates these recipes based on the user's personalized data, ensuring that the suggested meals are not only nutritionally optimized but also visually appealing. Recipes provided are optimized so that the user can prepare the meal in less than <a href="https://www.foodnavigator.com/Article/2023/04/13/youniq-app-uses-ai-to-optimise-personalised-nutrition">15 to 20 minutes</a>.To make the recommended recipes more actionable, Youniq has partnered with several grocery retailers, enabling users to have the necessary ingredients delivered to their doorstep within <a href="https://www.foodnavigator.com/Article/2023/04/13/youniq-app-uses-ai-to-optimise-personalised-nutrition">two hours</a>. Additionally, the app <a href="https://www.foodnavigator.com/Article/2023/04/13/youniq-app-uses-ai-to-optimise-personalised-nutrition">can scan the ingredients</a> already available in the user's refrigerator and suggest recipes accordingly, minimizing the need for additional shopping trips.In <a href="https://www.foodnavigator.com/Article/2023/04/13/youniq-app-uses-ai-to-optimise-personalised-nutrition">April 2023</a>, Youniq Health announced its plans to expand into the UK market, recognizing the country's potential for its English-language app.The company noted that as of <a href="https://www.youniq.health/">July 2024</a>, its app was available globally; however, its grocery delivery option was only available to US-based users.Key customers and partnershipsAs of July 2024, the company partnered with employers to offer employees access to its platform, as healthier employees can lead to reduced healthcare costs. Additionally, Youniq partnered with hospitals to provide nutrition programs for patients, assisting them in maintaining optimal diets after procedures.

Youniq

ZOE is a personalized nutrition provider that aims to provide tailored dietary recommendations based on an individual's biological needs. Members begin by requesting at-home testing kits priced at USD 294 as of July 2024, the results of which are analyzed by the company. Based on the analysis of the testing kit, which includes tests for blood fat, gut microbe, and standardized test meals, users can utilize the company’s app to analyze and find meals best suited to their individual needs.Meals analyzed are assigned a ‘ZOE score’ between 0 and 100, with higher scores being more nutritional. Based on these scores, users are able to build meals, discover new recipes, track their individual progress, and combine, swap, and add food to planned meals to optimize their nutrition.Additionally, through the app, users gain access to qualified nutrition coaches for live chats and access educational material curated by scientists.The company additionally offers a wholefood supplement developed using over 30 plants called ‘Daily30+,’ which it offers on a subscription basis of GBP 39 (USD 51) for one month’s worth of servings or GBP 133 (USD 172) for four months’ worth of servings.As of <a href="https://zoe.com/our-science#research-updates">July 2024</a>, the company was also conducting a clinical trial on the effects of a personalized nutrition program on cardiometabolic health. As a part of the study, users could sign up to be participants and would be eligible to receive a blood sugar monitor for tracking the effectiveness of following ZOE’s personalized nutrition program with regard to cardiometabolic health. The monitor is included in the initial testing package if users opt in when ordering the at-home testing kit.

Lifesum is a digital nutrition platform that helps users build healthier eating habits through its innovative app. Founded in Stockholm, Sweden in 2013, the company provides a comprehensive suite of features to track meals, habits, and body measurements, enabling users to achieve their health and wellness goals. As of June 2024, Lifesum has over 65 million users worldwide across 250 countries, supporting 11 languages.The app offers a user-friendly food diary allowing users to log meals by searching a database, scanning barcodes, or manually entering items. It tracks calorie intake, hydration levels, exercise routines, and provides personalized diet plans tailored to individual preferences and objectives, such as ketogenic, high protein, Scandinavian, or Mediterranean diets. Lifesum's premium subscription unlocks additional features like detailed nutrient tracking, advanced analytics, and a vast library of healthy recipes.In <a href="https://www.prnewswire.com/news-releases/lifesum-shakes-up-european-wellness-with-transformative-lykon-acquisition-302171999.html">June 2024</a>, Lifesum announced its transformative acquisition of LYKON, a biomarker-based personalized nutrition company in Germany. This aimed to revolutionize Lifesum's service by integrating LYKON's pioneering technology, enabling users to access personalized nutrition and wellness recommendations based on medical-grade biomarker testing and analysis.Key customers and partnershipsIn addition to offering its services directly to users, Lifesum partners with enterprise clients to offer its solution to employees as part of a work benefit. The company noted that as of <a href="https://www.prnewswire.com/news-releases/lifesum-shakes-up-european-wellness-with-transformative-lykon-acquisition-302171999.html">June 2024</a>, it offered its solution to over 100 enterprise clients, including <a href="https://yulife.com/blog/lifesum-partnership/">YuLife</a>, <a href="https://leadiq.com/c/lifesum/5a1d8afd240000240065b0ce#:~:text=Corporate%20Wellness%20Partnerships%20Lifesum%20has,%2C%20General%20Electric%2C%20and%20PayPal.">PayPal, General Electric, and Amazon</a>.Additionally, the company has collaborated with companies to increase the functionality of its platform.In <a href="https://lifesum.com/page/lifesum-and-openesg-partner-to-connect-nutrition-and-sustainability">August 2023</a>, the company partnered with OpenESG, a global sustainability GenAI platform, to help users see how their dietary choices affect the climate.In <a href="https://lifesum.com/page/lifesum-and-oura-partner-to-connect-nutrition-and-sleep-via-health-connect-by-and">May 2023</a>, Lifesum partnered with smart ring provider ŌURA to provide users with a sleep-tracking feature. The feature allows users to analyze how their diet affects their sleep and vice versa.In <a href="https://www.prweb.com/releases/digital-health-app-lifesum-teams-up-with-amazon-to-bring-nutrition-coaching-to-newly-unveiled-amazon-halo-860278838.html">August 2020</a>, the company partnered with Amazon to offer Lifesum’s nutrition coaching feature through Amazon Halo. Through the partnership, users of Amazon Halo could access nutritional challenges and health content provided by Lifesum.

Lifesum

MyFitnessPal is a mobile app that helps users track their diet and physical activity to achieve health and weight goals. With a database featuring millions of food items, the app enables precise logging of nutritional intake, aiding individuals in making informed dietary choices. It provides a user-friendly interface for recording consumed foods, calculating calories, and monitoring nutrient breakdown, including carbohydrates, proteins, fats, vitamins, and minerals.In addition to diet tracking, MyFitnessPal allows users to log their physical activities, such as running, walking, or gym workouts. Based on the recorded information, the app calculates the calories burned from these activities and updates the overall calorie balance. Users can set personalized goals for weight loss, gain, or maintenance, and the app tracks progress toward these objectives, providing insightful charts and reports.Key customers and partnershipsMyFitnessPal <a href="https://support.myfitnesspal.com/hc/en-us/articles/360032274232-What-kind-of-products-and-apps-work-with-MyFitnessPal">integrates</a> with various fitness trackers and apps, enabling data synchronization and automatic updates. This integration includes popular devices and platforms such as Apple Watch, Fitbit, Garmin, Samsung Health, and Google Fit. By connecting with these third-party services, MyFitnessPal offers users a comprehensive view of their health and activities, fostering a holistic approach to wellness.

MyFitnessPal

Limbo is a digital weight loss and body transformation service that guides users to healthier habits by leveraging real-time biodata from wearables, including a continuous glucose monitor (CGM), an app, and a combination of human coaches and AI. The service is based on over 30 years of research by Co-Founder and Physiologist Tony Martin, focused on understanding how blood glucose levels regulate the body's energy system.Limbo's approach revolves around monitoring users' blood glucose levels and providing personalized feedback and nudges to help them make better food choices and lifestyle adjustments. The goal is to flatten users' blood glucose levels, which Limbo refers to as the "Limbo line" by reducing the consumption of carbohydrates, sugars, and processed foods. This, in turn, is believed to promote weight loss and improve overall health.The service involves wearing a CGM sensor, which continuously tracks users' glucose levels, and a smart wristband that monitors various biometrics, including heart rate, steps, and sleep patterns. Users also receive a smart scale to track their body weight, body fat, and muscle mass. This data is then analyzed by Limbo's AI system and human coaches, who provide tailored feedback and guidance through the Limbo app.As of July 2024, the company operated on a subscription model, initially charging users GBP 295 (USD 381) for access to its services, after which users could choose from several subscription packages ranging from GBP 120 (USD 155) per month to GBP 160 (USD 207) per month. The company also offers a monthly non-subscription package for GBP 195 (USD 252) per month.

Limbo

Providers of tailored dietary recommendations based on an individual's genetics and lifestyle for optimal wellness and disease prevention. This also includes calorie-counting apps that assist with weight loss and management

Designers of tailored dietary plans to address root causes of chronic diseases and symptom management

Companies that develop and offer supplements and nutraceuticals focused on enhancing health, addressing nutrition deficiencies and supporting overall wellness

Companies that provide personalized food services, including medically tailored meals and a marketplace for diverse dietary products to meet individual needs

Companies that offer virtual consultations from dietitians and nutritionists offering guidance via personalized nutrition plans, lifestyle and dietary assessments, and a focus on long-term health and wellness

Some functional nutrition offerings are based on the genomic profiles of individuals to identify personalized solutions

Most functional nutrition companies offer nutrition solutions via digital mediums such as mobile applications; virtual consultations are also a part of the industry

Most functional nutrition companies provide personalized nutrition solutions in the form of meal plans, supplements, and prepared meals

The products/platforms offered by most companies utilize AI/ML to enhance their offering

DayTwo

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless